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AIMS
The palatability of a new paediatric formulation of valaciclovir was assessed in children and their parents: non-inferiority of the
new paediatric formulation (test formulation) compared to the reference formulation was investigated.
METHODS
In vivo palatability testing was performed in a randomized, two-period, multicentre, cross-over study. Children and their parents
scored the liking of the new paediatric valaciclovir formulation and the reference formulation on a 100 mm visual analogue scale
(VAS). To support formulation development and palatability testing, electronic tongue measurements were applied.
RESULTS
The electronic tongue measurement indicated taste-masking capabilities for three different formulations in the developmental
phase. A glycerol-based formulation was further tested and compared to the reference formulation prepared out of crushed and
suspended tablets. The mean difference (95% CI) in VAS scores between both formulations, as indicated by the children (n = 20),
was 2.4 (8.5, 13) mm, in favour of the new paediatric valaciclovir formulation. The mean (95% CI) difference in VAS scores
indicated by the parents (n = 20) was 0.9 (12, 9.8) mm.
CONCLUSION
The palatability of the new paediatric valaciclovir formulation was considered non-inferior to the reference formulation prepared
out of crushed tablets. We were able to optimize the study design and number of children to be included in the palatability testing
by using electronic tongue measurements.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Acceptable drug formulations for children are often lacking. Valaciclovir is a drug for which there is a need for an
appropriate paediatric formulation.
• Palatability is a key characteristic for acceptability of oral drug formulations and compliance, especially in children.
• Experience to test the acceptability of drug formulations in children is limited.
WHAT THIS STUDY ADDS
• This is the ﬁrst study in which results from palatability testing in children and adults, as well as results from an electronic
tongue assessment, are simultaneously available.
• The number of children needed for a comparative taste assessment can be lowered by application of an electronic tongue
measurement during the development of a new paediatric formulation.
• The palatability of the new paediatric valaciclovir formulation was non-inferior to the reference formulation prepared out
of crushed tablets.
Introduction
The palatability of oral drug formulations is a key characteristic
for the acceptability and compliance to drug therapy, especially
for children [1–3]. This aspect is emphasized by the regulatory
authorities in the ‘Guideline on pharmaceutical development
of medicines for paediatric use’, in which a veriﬁcation of the
acceptability of a new paediatric formulation prior to its
approval is demanded [3]. In addition to this, the Paediatric
Regulation of 2006 requests the development of appropriate
formulations for children, but without performance of unnec-
essary clinical trials in children [4]. Palatability testing is best
performed in the paediatric target population due to high dif-
ferences in taste preferences between adults and children, and
also between healthy and sick children [2]. However, it is debat-
able when a drug formulation can be considered acceptable,
and how acceptability should best be tested in children [5].
Research is needed to determinewhichmethods are best to test
for acceptability of different formulations, for different diseases
and for children of different ages and stages of development.
Experience in testing the acceptability of drug formulations in
children is still limited [6–10]. General considerations for
performing taste trials in children are included in the EMA
reﬂection paper: “Formulations of choice for the paediatric
population” [2]. The validity of the methods used for sensory
evaluation varies with the age of the children. A facial hedonic
scale and/or a visual analogue scale are commonly used in taste
assessments of drug formulations in young children [10]. Also,
the forced-choice tracking procedure and rank-order method
can be used to assess taste.
In general, palatability testing of drug formulations with hu-
man taste panels is reluctantly chosen and hampered by ethical
concerns, toxicological aspects, high costs andpoor reproducibil-
ity [11]. Taking all regulatory, ethical and statistical requirements
into account, use of in vitromethods for the taste assessment of
oral drug formulations might be a favourable alternative.
The electronic tongue is a promising tool for use in in vitro
taste assessments [9]. These instruments are commonly
equipped with a sensor array and based on electrochemical
measurement principles including potentiometry, voltamme-
try and amperometry [12–14]. Most of the used electronic
tongue sensors are potentiometric membrane electrodes fol-
lowing theNernst law and theirmembrane potentials are corre-
lated to at least one reference electrode [11–13]. The sensor
responses are caused by interactions of the sample molecules
with incorporated components of the electrode membrane.
Currently, two commercially available electronic tongue sys-
tems are employed for the taste assessment of drug formula-
tions: the α-Astree (AlphaMOS, Toulouse, France) and the
taste sensing systems TS-5000Z and SB402B (Insent Inc.,
Atsugi-Shi, Japan) [13–15]. In the case of the TS-5000Z and
SB402B, different sensors are dedicated to different tastes, such
as bitterness and sourness. The α-Astree and non-commercially
available electronic tongues work cross-selectively, meaning
that one sensor is dedicated to a combination of different
tastes [15]. Even though electronic tongues are commonly
used tools in the development of properly taste-masked drug
formulations, the obtained results are only a relative interpre-
tation of taste [9]. A relationship between electronic tongue
measurements and human taste has been demonstrated to
some extent in adults, but not in children [12, 14, 16–18].
Valaciclovir is used for the treatment and prophylaxis of
herpes simplex virus and varicella zoster virus infections [19].
However, in Europe, its use is off-label in children below the
age of 12 years. The US Food and Drug Administration
(FDA) label information describes the preparation of an oral
liquid formulation from crushed tablets, but this formulation
has to be discarded after 28 days [20]. To overcome practical
problems associated with the formulation prepared out of
crushed tablets, such as the short shelf-life and obstruction
of feeding tubes, we developed a new extemporaneous paedi-
atric valaciclovir formulation, as described previously [21].
The aim of this study was to investigate the palatability of
this new extemporaneous valaciclovir formulation, com-
pared with the frequently used extemporaneous formulation
from crushed and suspended valaciclovir tablets. In vivo palat-
ability testing of the new paediatric valaciclovir formulation
was performed in children and their parents. The electronic
tongue was applied for the formulation development as well
as for the in vitro taste assessment of the new formulation.
Methods
Materials
Electronic tongue. For the preparation of the standard and
washing solutions for the electronic tongue, potassium
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chloride (Gruessing, Filsum, Germany), potassium hydroxide
(Gruessing, Filsum, Germany), tartaric acid (AppliChem,
Darmstadt, Germany), hydrochloric acid (Merck, Germany)
and absolute ethanol (VWR international, Darmstadt,
Germany) were used. The measurements were performed
with a sensor array consisting of eight commercially
available sensors (Insent Inc., Atsugi-Shi, Japan), each
dedicated to a deﬁned taste: SB2AAE: umami; SB2CT0:
saltiness; SB2AE1: astringency; SB2CA0: sourness; SB2AC0:
bitterness (cationic substances); SB2AN0: bitterness
(cationic substances); SB2BT0: bitterness (cationic
substances); SB2C00: bitterness (anionic substances).
Valaciclovir formulations. Valaciclovir formulations were
prepared based on valaciclovir hydrochloride monohydrate
(Duchefa Farma, Haarlem, The Netherlands), glycerol
(Spruyt Hillen, IJsselstein, The Netherlands), maltodextrin
(Kleptose® Linecaps, Roquette, France), citric acid (Duchefa
Farma, Haarlem, The Netherlands), disodium
hydrogenphosphate (Spruyt Hillen, IJsselstein, The
Netherlands), OraSweet® SF (Paddock Laboratories LLC,
Minneapolis, US) and puriﬁed water. Samples for the
formulation development comprised valaciclovir in three
different vehicles, named formulations A, B and C.
Formulation A contained glycerol as main excipient,
formulation B maltodextrin, and formulation C contained
both glycerol and maltodextrin as excipients (see Table 1).
The test formulation for the in vivo palatability assessment
was chosen based on the results of the ﬁrst electronic tongue
measurement combined with the results of pharmaceutical
testing (including stability). The reference formulation was
derived from the extemporaneous liquid made from crushed
innovator tablets as described in the FDA label information
with OraSweet® SF as suspension vehicle [20, 22].
Electronic tongue measurement protocol and
sample preparation
Electronic tongue measurements were performed using the
taste sensing system SA402B (Insent Inc.) and the measure-
ment protocol according to Woertz et al. [23]. Two electronic
tongue measurements were performed: (a) one in the devel-
opmental phase and (b) one to support the in vivo palatability
testing. The most reliable use of electronic tongue measure-
ments for drug formulation development requires a
concentration-dependent behaviour of the applied sensors.
Therefore, the behaviour of the sensors to different con-
centrations of valaciclovir in only water (as valaciclovir
hydrochloride monohydrate, Duchefa Farma, Haarlem,
The Netherlands) was determined prior to evaluating the
drug formulations. For this purpose, calibration samples con-
taining 0, 0.2, 2, 20 and 50 mg ml1 valaciclovir were
analysed.
Samples with 0, 20 and 50 mgml1 valaciclovir of the for-
mulations A, B and C were tested for the formulation devel-
opment. The samples for the taste assessment of the newly
developed formulation [21] comprised 20 mg ml1 and
50 mg ml1 valaciclovir in the chosen vehicle, or 25 mg ml1
and 50 mg ml1 in OraSweet® SF (Table 1).
Table 1
Composition of formulations tested by the electronic tongue: (a) in the developmental phase and (b) to support the in vivo palatability testing
Composition of the formulation Abbreviation
Valaciclovir
concentration (mg ml1)
(a) Formulations developmental phase
Formulation A: water, glycerol (42.5%), citric acid, disodium hydrogenphosphate A1/A2 0
Val20_A 20
Val50_A 50
Formulation B: water, maltodextrin (0.5:1 mol/mol valaciclovir), citric acid,
disodium hydrogenphosphate, sorbic acid
B1/B2 0
Val20_B 20
Val50_B 50
Formulation C: water, glycerol (25.5%), maltodextrin (0.5:1 mol/mol valaciclovir),
citric acid, disodium hydrogenphosphate
C1/C2 0
Val20_C 20
Val50_C 50
Water Val20 20
Val50 50
(b) Formulations for in vivo palatability assessment
Test (formulation A): water, glycerol (42.5%), citric acid, disodium hydrogenphosphate Test 0
Val20_test 20
Val50_test 50
Reference: OraSweet SF®: water, glycerin, sorbitol, sodium saccharin, xanthan gum,
citric acid, sodium citrate methylparaben, potassium sorbate, propylparaben,
citrus-cherry ﬂavour.
Reference 0
Val25_ref 25
Val50_ref 50
Water Val20 20
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Data analysis of the electronic tongue
Data obtained by electronic tongue measurements were eval-
uated using Microsoft Excel®, OriginPro 9.0G and Simca
13.0.2 (Umetrics, Sweden) for univariate and multivariate
data analysis. The sensor responses were corrected with an
external standard solution of 0.5 mM quinine hydrochloride
dihydrate (Buchler GmbH, Germany). Each sample was mea-
sured four times, and the last three measurements were used
to calculate the mean values and standard deviations. The
sensor response pattern of the vehicles (formulations without
valaciclovir) was used as a positive reference for taste-masking
efﬁciency (i.e. the best taste possible to achieve with the vehi-
cle). Conversely, the pure drug solutions with 20mgml1 and
50 mg ml1 valaciclovir in water were used as a negative taste
reference. For example, if one of the bitter sensors detects a re-
duced sensor signal for a drug formulation compared to the
pure drug solution, a taste-masking effect of the excipients
can be assumed [9, 12, 13, 24, 25]. This indicates taste-
masking efﬁciency of the excipients.
To perform the multivariate statistical analysis, a princi-
pal component analysis (PCA) was performed to objectively
compare the drug formulations, the pure drug solutions
(20 mg ml1 and 50 mg ml1 valaciclovir in water) and the
vehicles. To individually quantify the differences in the taste
pattern of the tested samples of the test and reference formu-
lations, the Euclidean distances were calculated using the
formula:
d p; qð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑
n
i¼1
qi  pi
 
2
s
where p and q are the sensor responses of the different sensors
and samples being compared.
In vivo palatability testing
Study population. Children were eligible if aged at least 4 and
less than 12 years and having received (val)aciclovir in the
past, using valaciclovir as prophylaxis at that time, or had a
high probability of future use, such as children with primary
immune deﬁciency or recipients of haematopoietic stem cell
transplantation. Children and one of their parents
attending the outpatient clinic of the Leiden University
Medical Centre, Radboud University Medical Centre or the
University Medical Centre Utrecht in The Netherlands, were
asked for their participation. Children with a sensitivity or
idiosyncrasy to medicinal products or excipients were
excluded, as were children with any condition that
inﬂuences taste sensation (such as upper respiratory
infection, mucositis or use of medication that inﬂuences
taste perception).
The Central Committee on Research Involving Human
Subjects (CCMO) provided ethical approval for performance
of the assessment (NCT01682109). The trial conformed to
the principles of the Declaration of Helsinki and regulations
concerning clinical trials, as well as the ‘Code of conduct
relating to expressions of objection by minors participating
in medical research’ (http://www.ccmo.nl/en/codes-of-
conduct).
Study design of the palatability testing. The palatability
assessment was a randomized, two-period, multicentre,
cross-over study. The design of the study was based on the
EMA Reﬂection Paper and description of conducting taste
assessment trials in children [2, 6–8, 26]. The main outcome
was based on liking indicated by the subjects on a 100 mm
visual analogue scale (VAS) combined with ﬁve smiley faces
(Figure 1). Prior to the start of the study, signed informed
consent was given by the legal guardian(s) for participation
of the child. If the parent also participated, signed informed
consent was given for their own participation. Only after
also the child agreed to participate in the assessment were
study procedures started.
The child and parent were together taken to a private area.
First, the 100 mm VAS-smiley scale was explained and prac-
tised by the child [27]. To have the same ‘taste starting point’,
all subjects tasted 4 ml (children 4–8 years) or 8 ml (children
8–12 years and the parent) of the samemixed valaciclovir for-
mulation (a 1:1 mixture of the test and reference formula-
tion). After this, 4 ml or 8 ml of the test and reference
formulation were presented to the subject in a plastic medica-
tion cup in randomized order. To neutralize taste before and
between tastings, subjects ate a cracker and rinsed their
mouth with water. After tasting each of the three formula-
tions, the subject rated their liking on the VAS-smiley scale.
Parents were also asked to record which formulation they
thought their child would favour.
Treatment order was randomly allocated using random
values created with SPSS® software version 18.0.2 (SPSS Inc.,
Figure 1
Applied combined 100 mm visual analogue/facial hedonic scale
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1993–2007). Randomization was stratiﬁed for sex and age in
blocks of four. After the mixed valaciclovir formulation,
group A ﬁrst received the test formulation followed by the
reference formulation, group B received the reference formu-
lation ﬁrst.
Correlating the results of an electronic tongue measure-
ment with results from a human taste panel increases the
value of the information from both measurements. Since
the ability to describe basic tastes develops during the ﬁrst
decade of a child’s life, not the children but the parents were
asked to describe the basic tastes of the different valaciclovir
formulations [28, 29]. Parents could report all the tastes that
were applicable: bitter, sweet, salt, sour or other, regardless
of the intensity of taste.
With an expected difference between VAS scores of the
formulations of 10 mm (see electronic tongue measurements
in Results section), a standard deviation of the within-subject
differences of about 30 mm and a non-inferiority margin of
10 mm, a total of 20 children was needed to reach a power
of 80% to demonstrate non-inferiority of the test formulation
compared to the reference formulation.
Data analysis of the palatability testing. The mean difference
in palatability of the test and reference formulation as
indicated by the children on the 100 mm VAS-smiley scale
was used as primary outcome measure. A difference of
10 mm or less was considered negligible. Non-inferiority
was shown when the lower limit of the 95% two-sided
conﬁdence interval (95% CI) for the difference in VAS
scores of the formulations was above 10 mm. The primary
analysis was a model without carryover, with the
formulation and period as ﬁxed effects. A model with
carryover effects (interaction period by formulation) was
used to verify whether an identical trend in the ordering of
the formulations was found and is regarded as a measure of
the robustness of our ﬁndings. The scores given by the
parents were analysed in a similar way. To determine
whether there was a correlation for the rating of the child
and the parent, the correlation coefﬁcient with repeated
observations within families was calculated [30]. Subjects
not able to evaluate all three liquids were excluded from the
data analysis. Statistical analysis was performed in SPSS®
(software version 18.0.2, SPSS Inc., 1993–2007).
Results
Electronic tongue measurement as support for
the formulation development
Concentration-dependent sensor responses towards
valaciclovir were observed for all applied sensors. Sensors
SB2CT0 (saltiness), SB2AE1 (astringency) and SB2BT0 (bit-
terness of cationic substances) were found to be most sen-
sitive, showing the best concentration dependency
towards the pure drug substance indicated by the largest
slope. (Slopes (mean ± SD): SB2BT0: 54.1 ± 0.2; SB2CT0:
43.8 ± 0.3; SB2AE1; 43.4 ± 0.3; SB2AN0: 28.0 ± 0.3;
SB2C00: 22.7 ± 0.3; SB2CA0: 19.1 ± 0.5; SB2AC0: 17.6 ±
0.2; SB2AAE: 8.8 ± 0.3).
The three different drug-containing formulations (formu-
lation A, B and C, Table 1), each with different concentrations
of valaciclovir, were analysed by the employed sensor array.
The PCA was based on the ﬁrst two principal components
explaining 92% of the information given by the sensor re-
sponses (principal component 1: 71.1%, principal compo-
nent 2: 20.9%, Figure 2). In this case, the ﬁrst principal
component deﬁnes the bitterness of the investigated sample:
samples located on the left side of the map (vehicles) are less
bitter than those located on the right side of the map (drug-
containing formulations). Merging sensorial information in
such a map helps to assess how different samples are detected
by the sensors. For example, it indicates a similar taste for the
drug formulations ‘Val20_A’ and ‘Val20_C’ (Figure 2). In
general, taste-masking of valaciclovir was observed in all in-
vestigated drug formulations. As the formulations containing
maltodextrin had an inferior physical stability (pharmaceuti-
cal testing, unpublished data), formulation A was selected for
further investigations.
Electronic tongue measurement to evaluate the
formulations for in vivo palatability testing
The in vitro taste-masking capability of the test formulation
(formulation A) was compared to the reference formulation
(Table 1). The obtained sensor responses were initially evalu-
ated by multivariate data analysis by performing a PCA with
two principal components (Figure 3). The ﬁrst principal com-
ponent described 88.2% of the sensor information. No differ-
entiation as mentioned above (right side: bitter; left side: less
bitter) was possible. In this case the main information along
the x-axis differentiates the two vehicles. Based on observa-
tions during sample handling, this was most probably due
to the different ﬂuidity of the samples, indicating different
viscosities. Interpreting the map, more viscous samples are
located on the left side and less viscous on the right side.
Bitterness might be differentiated along the y-axis.
The small distances between samples ‘Val20_test’ and
‘test’ demonstrate a good taste-masking effect of the vehicle.
Figure 2
PCA map for the formulation development of valaciclovir (mean,
n = 3, R2 = 0.920, Q2 = 0.508): Val20/50: valaciclovir in water (20
and 50 mg ml1); A1/2, B1/2 and C1/2: vehicles; Val20/50_A/B/C:
valaciclovir in vehicles A, B and C (20 and 50 mg ml1)
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Conversely, the test sample containing 50 mg ml1
valaciclovir (Val50_test) was located close to the pure drug
solution (Val20), indicating only a minor taste-masking
effect. The reference formulations (Val25_ref and Val50_ref)
were located close to each other but further away from their
corresponding vehicle (reference). This indicated differences
in taste sensation.
The calculated Euclidean distances are shown in Figure 4
and Table 2. For the test and reference formulations, the sam-
ples containing 20mgml1 and 25mgml1 valaciclovir dem-
onstrated an improved taste-masking efﬁciency indicated by
higher distances between the drug formulations to the pure
drug solution and lower distances to their corresponding
vehicles. Both calculated Euclidean distances of the reference
formulations were higher than those of the test formulations
(Table 2), indicating that the reference formulations were less
similar in the taste pattern to either the pure drug solution or
the reference vehicle. Due to this contradictory outcome, the
test formulation was assumed to better taste-mask
valaciclovir than the reference formulation. As a result, a dif-
ference between liking of the test and reference formulation
of approximately 10 mm on the 100 mm VAS score in favour
of the new paediatric formulation was expected for the palat-
ability assessment in children.
In vivo palatability testing
Twenty-one children and 20 parents were included in the
taste assessment. One child tasted only two formulations,
and the parents of another child were not able to attend.
Therefore, VAS scores of all three liquids from 20 children
and 20 parents (19 child–parent pairs) could be included in
the analysis. Characteristics of the subjects and VAS scores
are displayed in Table 3. For the children, mean (95% CI)
VAS scores were 26 mm (18, 34) for the test formulation and
24 mm (16, 32) for the reference formulation with a mean
difference (95% CI) of 2.4 (8.5, 13) mm, in favour of the test
formulation. The test formulation can therefore be consid-
ered non-inferior to the reference formulation. Based on the
VAS scores of the test and reference formulations, seven chil-
dren (35%) preferred the test formulation, four (20%) the
reference formulation and nine (45%) children indicated a
difference of 10 mm or less between the formulations. Inclu-
sion of the interaction of period by formulation as a ﬁxed ef-
fect did not have a signiﬁcant effect (P = 0.871) and therefore
no carryover effects were observed.
For the parents, mean (95% CI) VAS scores were 45 (36,
54) mm for the test formulation and 46 (37, 55) mm for the
reference formulation and a mean difference (95% CI) of
0.9 (12, 9.8) mm, in disadvantage of the test formulation.
Based on the VAS scores of the formulations, six parents
(30%) preferred the test formulation, seven (35%) the refer-
ence formulation and seven (35%) indicated a difference of
Figure 3
PCA map comparing the test and reference formulation containing
valaciclovir in different concentrations (mean, n = 3, R2 = 0.990,
Q2 = 0.932): Val20: valaciclovir in water (20 mg ml1); Test: vehicle
of test formulation; Reference: vehicle of reference formulation;
Val20/50_test: valaciclovir test formulation (20 and 50 mg ml1);
Val25/50_ref: valaciclovir reference formulation (25 and
50 mg ml1)
Figure 4
Euclidean distances of the drug formulations compared to either the
corresponding vehicle (black) or the corresponding samples of
valaciclovir in water (red) (n = 3): Val20/50_test: valaciclovir in vehi-
cle of test formulation (20 and 50 mg ml1); Val25/50_ref:
valaciclovir in vehicles of reference formulation (25 and 50 mg ml1)
Table 2
Euclidean distances (mV) between formulations for the test and ref-
erence formulations (n = 3, mean ± SD). Smaller Euclidean distances
indicate that the two samples (either ‘dosing vehicle vs. formulation’
or ‘pure drug solution vs. formulation’) are more similarly detected
from the sensor array (8 sensors) of the electronic tongue
Formulation
Dosing vehicle
vs formulation
Pure drug solution
vs formulation
Test (formulation A)
20 mg ml1 0.94 ± 0.05 2.48 ± 0.08
50 mg ml1 2.18 ± 0.04 1.62 ± 0.05
Reference
(OraSweet® SF)
25 mg ml1 3.36 ± 0.06 5.51 ± 0.04
50 mg ml1 4.63 ± 0.04 4.53 ± 0.03
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10 mm or less between formulations. The test for the interac-
tion of period by formulation showed a P-value of 0.074 and
therefore carryover effects cannot be ruled out for the par-
ents. When only the results from the ﬁrst period are analysed:
eleven parents tasted the test formulation and nine the refer-
ence formulation. In this way, the mean (95% CI) difference
between the VAS scores of the formulations was 12 (4.5,
28.6) in favour of the test formulation.
VAS scores of the children and the parents did not show a
correlation (correlation coefﬁcient = 0.03, P = 0.91). Predic-
tions made by 18 parents as to which formulation would be
preferred by their child showed six (33%) correctly predicting
their child’s preference and ten (56%) choosing a different
formulation. Two children were not able to show a
preference.
Combined electronic tongue and taste testing
results
Nineteen parents assigned basic tastes to the formulations.
The predominantly chosen basic tastes by the parents for
both the reference and the test formulation were bitterness
and sweetness. Twelve parents (63%) thought the reference
formulation had a bitter taste and eight parents (42%)
thought the test formulation had a bitter taste. The high per-
centage of parents tasting bitter corresponds to the results
found by the electronic tongue, in which the bitter sensor
(SB2BT0) was the most distinctive for valaciclovir, together
with sensor signals of the saltiness and astringency receptor.
The parents did not predominantly choose the saltiness taste.
Twelve parents (63%) indicated the reference formulation as
being sweet and eleven parents (58%) thought the test formu-
lation was sweet.
Discussion
The palatability of the newly developed paediatric
valaciclovir formulation was non-inferior to the reference
formulation in children. No signiﬁcant differences were
found between the liking of the new paediatric formulation
of valaciclovir, compared to crushed and suspended tablets.
Non-inferiority was shown for the children, but not for the
parents, as the lower margin of the 95% CI was just below
10% (11.6%). This can be explained by the higher mean
VAS score of the reference formulation compared to the test
formulation, and the somewhat higher variance in VAS
scores of the parents, compared with the children. Variability
in preference of the test or reference formulation was also
observed between the subjects: 35% of the children and
30% of the parents preferred the test formulation and 20%
of the children and 35% of the parents preferred the reference
formulation. No carryover effects were observed for the chil-
dren, but carryover effects for the parents could not be ruled
out. When only the results from the ﬁrst period are analysed,
non-inferiority of the reference formulation was observed,
also for the parents. When carryover effects are observed, an
alternative for an AB crossover design should be chosen
[31]. However, this would imply a possible larger burden of
the assessment such as a longer assessment, more visits or
more subjects, which are undesirable in studies involving
paediatric patients.
No correlation was found between the liking of the for-
mulations by the children and their parents. Only a minority
of the parents were able to correctly predict the preferred for-
mulation for their child. This conﬁrms that taste assessments
of (new) paediatric formulations should be performed in
children [2].
This is the ﬁrst study in which results from palatability
testing in children and adults as well as results from an elec-
tronic tongue assessment are simultaneously available. Based
on the results from the electronic tongue measurement, it
was expected that the test formulation would have a slightly
better palatability than the reference formulation. Without
the use of the electronic tongue in the palatability testing,
no difference in VAS scores would be expected and the num-
ber of children to be included would have been more than
3.5-fold higher. The expected difference of 10 mm in VAS
score between the formulations could not be conﬁrmed, nor
ruled out. An explanation could be the complexity of tastes
of both formulations. The pure active pharmaceutical ingre-
dient valaciclovir has a bitter taste. The test and reference for-
mulation both contain citric acid, which has a sour taste, and
both contain sweet tasting substances. However, sensors to
capture the complexity of sweetness were not available,
which is a limitation of this study. Sweetness could thus not
be measured with the electronic tongue. Children especially
mostly like sweetness, but it is generated by substances with
a wide molecular diversity. Sweetness sensors for selected
sweet-tasting substances have recently been developed and
development is extended to more complicated molecules
[12, 32, 33]. Validated sensors to measure sweetness are
needed for optimal in vitro evaluation of paediatric drug for-
mulations. Besides the complexity of tastes of the formula-
tions, also the use of a non-trained taste panel inﬂuences
the precision of the results. To develop a taste-masking strat-
egy during formulation development, more precise results are
desirable, encouraging the application of electronic tongues.
Aspects such as texture, smell and appearance of a formula-
tion can inﬂuence acceptability [2, 3], but were neither scored
Table 3
Baseline characteristics and results from scores on the visual ana-
logue scale (VAS score)
Baseline characteristics
(median, range)
Children Parents
n = 20 n = 20
Age, years 8.7 (6.3, 11.9) 41 (34, 54)
Sex (female/male) 6/14 11/9
Underlying condition
Primary immune deﬁciency 18
Stem cell transplantation 2
VAS scores (mm) (mean,
95% CI)
Test formulation 26 (18, 34) 45 (36, 54)
Reference formulation 24 (16, 32) 46 (37, 55)
Test – reference
formulation
2.4 (8.5, 13) 0.9 (12, 9.8)
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nor measured during the assessment. However, for accept-
ability, solutions are generally preferred over suspensions
[34]. The new formulation of valaciclovir is a solution, which,
for that reason, would be preferred over the suspension pre-
pared out of crushed tablets.
One of the strengths of this study is that we were able to
perform palatability testing in a paediatric target population
using valaciclovir or with a high probability of future use. A
different paediatric population who could beneﬁt from the
new paediatric formulation of valaciclovir are (premature)
neonates. Because of the possible burden of the trial assess-
ments and the lack of experience with methods for accept-
ability testing of drug formulations in neonates, they were
not included in the study.
The difference in valaciclovir concentration between the
test and reference formulation (20 vs. 25 mg ml1, respec-
tively) is debatable. As was shown with the electronic tongue
measurement, a higher concentration of valaciclovir in water
results in a higher sensor signal and an assumed more
bitter-tasting formulation, which would be unfavourable for
the reference formulation. However, the choice was made to
use concentrations that would be used in clinical practice.
The concentration for the test formulation was based on
pharmaceutical stability testing and expected ease of
calculation of the volume to be administered. The
concentration of the reference formulation was as included
in the FDA label information, and would thus be used in daily
practice.
In conclusion, we found that in children, the palatabil-
ity of the new paediatric valaciclovir formulation was non-
inferior to the reference formulation prepared out of
crushed tablets. Next to a longer shelf-life than crushed
and suspended tablets combined with a comparable expo-
sure as tablets, the results of this palatability study further
support the use of the new extemporaneous paediatric for-
mulation as an alternative formulation for (crushed and
suspended) valaciclovir tablets. By applying an electronic
tongue measurement during the development and as
screening for the in vivo palatability testing, we were able
to optimize effort and number of children to be included
in a clinical trial.
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